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Abstract
Background: The Schistosomiasis Consortium for Operational Research and Evaluation (SCORE) focus is on randomized
trials of different approaches to mass drug administration (MDA) in endemic countries in Africa. Because their studies
provided an opportunity to evaluate the effects of mass treatment on Schistosoma-associated morbidity, nested cohort
studies were developed within SCORE’s intervention trials to monitor changes in a suite of schistosomiasis disease
outcomes. This paper describes the process SCORE used to select markers for prospective monitoring and the baseline
prevalence of these morbidities in four parallel cohort studies.
Methods: In July 2009, SCORE hosted a discussion of the potential impact of MDA on morbidities due to Schistosoma
infection that might be measured in the context of multi-year control. Candidate markers were reviewed and selected for
study implementation. Baseline data were then collected from cohorts of children in four country studies: two in high
endemic S. mansoni sites (Kenya and Tanzania), and two in high endemic S. haematobium sites (Niger and Mozambique),
these cohorts to be followed prospectively over 5 years.
Results: At baseline, 62% of children in the S. mansoni sites had detectable eggs in their stool, and 10% had heavy
infections (≥ 400 eggs/g feces). Heavy S. mansoni infections were found to be associated with increased baseline risk of
anemia, although children with moderate or heavy intensity infections had lower risk of physical wasting. Prevalence of
egg-positive infection in the combined S. haematobium cohorts was 27%, with 5% of individuals having heavy infection
(≥50 eggs/10 mL urine). At baseline, light intensity S. haematobium infection was associated with anemia and with lower
scores in the social domain of health-related quality-of-life (HRQoL) assessed by Pediatric Quality of Life Inventory.
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Conclusions: Our consensus on practical markers of Schistosoma-associated morbidity indicated that height, weight,
hemoglobin, exercise tolerance, HRQoL, and ultrasound abnormalities could be used as reference points for gauging
treatment impact. Data collected over five years of program implementation will provide guidance for future evaluation
of morbidity control in areas endemic for schistosomiasis.
Trial registration: These cohort studies are registered and performed in conjunction with the International Standard
Randomised Controlled Trial Registry trials ISRCTN16755535, ISRCTN14117624, ISRCTN95819193, and ISRCTN32045736.
Keywords: Schistosomiasis, Schistosoma haematobium, Schistosoma mansoni, Morbidity, Drug therapy, Praziquantel,
Africa, Cohort study, Kenya, Mozambique, Niger, Tanzania
Background
Human schistosomiasis, also known as bilharziasis, is a
tropical and sub-tropical disease that affects over 240
million people worldwide, with most infections occur-
ring in sub-Saharan Africa [1–3]. Schistosoma infections
account for at least 3.3 million disability-adjusted life
years (DALYs) [3, 4]. Active infection is found most
often among school age children [5–8], who acquire it
through contact with fresh water containing infected
snails. In Africa, morbidity is primarily caused by im-
munologic reactions to eggs that are produced either by
S. mansoni worms inhabiting the blood vessels of the in-
testines or by S. haematobium worms inhabiting vessels
of the genitourinary tract [1].
At present, the primary means of schistosomiasis con-
trol is mass drug administration (MDA) with the drug
praziquantel. Current WHO guidelines on how to con-
duct MDA for control of severe morbidity were devel-
oped in 2002 and 2006 [9, 10] and were based on expert
opinion. Because systematic evidence on the effective-
ness of alternative multi-year regimens is needed to bet-
ter define optimal approaches to control, the Bill and
Melinda Gates Foundation funded the Schistosomiasis
Consortium for Operational Research and Evaluation
(SCORE) in 2008, through a grant to the University of
Georgia Research Foundation [11, 12]. SCORE’s vision is
to answer strategic questions to inform efforts to gain
control of schistosomiasis in high-prevalence areas, to
sustain control and move towards elimination in areas
of moderate prevalence, and ultimately to eliminate
Schistosoma transmission in at-risk communities.
Current WHO guidelines for control of Schistosoma spe-
cies infections recommend an initial focus on prevention of
infection-associated morbidities through regular annual or
biennial MDA to limit cumulative damage from infection
and any subsequent reinfection [10]. The morbidities asso-
ciated with schistosomiasis include anemia [3, 13–15],
growth impairment [16–18], reduced memory, learning
[19], and fitness [3], along with chronic pain [3], chronic in-
flammation [14], and focal organ damage and scarring of
the colon and liver (S. mansoni) or of the genitourinary
organs (S. haematobium) [1]. A major effort of the SCORE
Project has been to perform multi-arm, multi-year,
randomized intervention trials that evaluate the effect of
timing and alternative approaches to MDA on changes in
prevalence and intensity of schistosomiasis in affected
African countries [12]. Because these studies also afforded
an opportunity to investigate changes in morbidity follow-
ing MDA, nested cohort studies of changes in
schistosomiasis-associated morbidity were instituted within
the SCORE intervention trials. This paper describes the
decision-making process regarding which markers to study,
and the subsequent design and implementation of pro-
spective cohort studies. The results are expected to inform
public health decision-making and design of neglected
tropical disease programs, and provide data for cost-
effectiveness analysis of different schistosomiasis control
strategies evaluated in SCORE operational research trials.
Methods
Study design
To evaluate changes in morbidity associated with MDA over
5 years, we have initiated a set of parallel prospective cohort
studies of children between the ages of 7 and 8 years enrolled
in the SCORE intervention trials in African country regions
with high prevalence of infection (>25%) with either S.
mansoni or S. haematobium [10]. In these cohort studies, we
follow a group of randomly selected 7–8 year old children in
villages randomly assigned to two different MDA interven-
tion arms as part of SCORE ‘Gaining Control’ trials
(ISRCTN16755535, ISRCTN14117624, ISRCTN95819193,
and ISRCTN32045736). Cohort children have been enrolled
from villages in the two arms of each study with divergent
MDA intervention schedules: the arm delivering annual
community-wide treatment (CWT, Arm A) and the arm
delivering school-based treatment every other year (SBT,
Arm B) (Fig. 1). To evaluate the effect of MDA on disease
caused by S. mansoni, cohorts were enrolled in Kenya and
Tanzania; to evaluate the effect of MDA on disease caused
by S. haematobium, cohorts were enrolled in Mozambique
and Niger. Morbidity in the selected cohort children is to be
evaluated serially at baseline, and after 3 and 5 years.
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Niger (in 2004) and Tanzania (in 2006) had previously
implemented national or sub-national MDA programs, in
collaboration with the Schistosomiasis Control Initiative,
that included annual or every-other-year anti-schistosomal
praziquantel treatment [20]. Although a number of com-
munities in Kenya’s western Lake Victoria region had been
screened and treated as part of prior S. mansoni research
[21], Kenya did not have a national schistosomiasis control
project at the outset of the current study. Likewise,
Mozambique did not yet have a national control program
at the beginning of the SCORE study.
Study development: identifying morbidity measures for
inclusion in the cohort study
In July 2009, SCORE leadership convened a meeting to
discuss infection-associated morbidity markers as poten-
tial study outcomes in a study of the impact of alternative
approaches to MDA. There was agreement that markers
used in the SCORE morbidity studies should be feasible to
perform in the field, as well as compelling to decision-
makers, and that the morbidity-marker research should
yield useful results in terms of program metrics for suc-
cess. It was agreed that the optimal design for the current
morbidity impact assessment was to create nested longitu-
dinal cohorts of children who could be available at base-
line, Year 3, and Year 5 for serial follow-up during the
course of the larger SCORE MDA trials.
The Schistosoma-associated morbidity outcomes that
were considered during the meeting and in follow-up dis-
cussions are listed in Table 1. Most of the measures con-
sidered assessed individual-level impact of MDA among
children, but some measures, such as household income
and reproductive health outcomes, indirectly assessed
family or community-wide impacts. It was ultimately
decided not to attempt to measure community-wide
externalities [22], as these would be difficult to measure
precisely, would take a longer time to manifest, and when
detected, would be difficult to attribute specifically to the
study interventions without concurrent collection of data
in a number of untreated control communities.
The criteria for marker selection included: i) the likeli-
hood that findings would be persuasive to program man-
agers and policy-makers; ii) the existence of prior evidence
suggesting a relationship between Schistosoma infection
and its incidence; iii) the likelihood that the marker could
Fig. 1 Diagram of the planned study arms for the SCORE cohort studies. As part of the larger SCORE randomized trials studying MDA delivery options
for communities with endemic S. mansoni or S. haematobium infections [12], seven and eight year-old children residing in villages randomized into
each of two SCORE project study arms were enrolled in prospective cohort studies of Schistosoma infection-related morbidities. In Arm A, communities
are to receive yearly community-wide MDA. In Arm B, treatment will be given to school age children every other year, with drug ‘holidays’ in Year 2
and Year 4. The present paper reports on baseline pre-treatment data from Year 1; follow up examinations are planned and will be reported for Year 3
and Year 5 in later publications
Table 1 Metrics considered for inclusion in SCORE morbidity
cohort studies
Recommended for study, and included in the cohort evaluation
protocol:
Anthropometric measures: age-standardized height, weight, body mass
index (BMI), mid-upper arm circumference (MUAC) [16–18]
Blood hemoglobin [3, 13–15]
Exercise tolerance measured by 20-m shuttle run (beep) test [23–26]
Health-related quality-of-life, measured by standardized PedsQL
survey instrument [27, 28]
Ultrasonography of the abdomen and liver (S. mansoni) or of the
kidneys and bladder (S. haematobium), using standardized protocols
[29, 30]
Considered, but not selected for study:
Individual-level outcomes
Indicators of the mechanism for anemia: Zinc protoporphyrin, ferritin,
hepcidin, C-reactive protein, Interleukin-6 [14, 31, 32]
Volitional activity (e.g., as measured by accelerometers, fitness
trackers) [33, 34]
Attention span [19, 35]
School performance, school completion rates [19]
Serologic measures of collagen metabolism [36]
Urine abnormalities, e.g., albuminuria, hematuria [3, 37]
Eosinophilic cationic protein (ECP) in urine [38]
Household or Population-level outcomes
Changes in religious participation [39]
Health system utilization [40]
Household income, productivity, work yield [22]
Community fertility and birth outcomes [41, 42]
Vaccine responses in babies [43]
The two sections indicate those that were selected and those that were not
selected for inclusion in the final protocol
Selected references for each considered outcome are cited in brackets after
each listing
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be reliably measured in areas with limited infrastructure; iv)
the cost of testing; and v) the potential for the marker to
change during the period of study observation.
In addition to the outcomes included in the baseline
dataset, data on mid-upper arm circumference (MUAC)
were requested in the final protocol. However, as these
MUAC data were incomplete and inconsistent, they
were dropped from the final analysis.
Selection of the cohort populations
The recruitment goal of the cohort study was to enroll
800 subjects from each of the four participating coun-
tries—400 from Arm A (receiving the most intensive
MDA by CWT) and 400 from Arm B (receiving less in-
tensive MDA via every other year by SBT) (Fig. 1). The
selection for study inclusion was conducted in a two-
step process – the first step involving village selection
and the second focused on the individual children within
those villages.
The large intervention trials in which the cohorts were
nested include 25 villages per arm. Four villages from
the most- and the less-intensive intervention arms were
randomly selected for inclusion in the cohort study.
However, investigators were permitted to select from a
restricted group of no less than 10 of the 25 villages in
each arm, which could be chosen, for example, based on
ease of access from the study base. In Kenya, because
fewer than 800 children were enrolled in the eight
selected villages, two additional villages were added to
each arm, yielding a total of twelve cohort study villages
in the western Kenya site.
Children in the selected villages were eligible for the
cohort study if they were age 7 or 8 at the start of the
study, attended a local school, and did not have a dis-
ability that precluded participation in all of the study
health measurements, in particular, the 20-m shuttle run
fitness test [23, 44]. If more than 100 children were
eligible, participants were to be randomly selected.
Baseline and follow-up evaluation of cohort children
At the time of enrollment into a cohort, each child under-
went a standard evaluation for Schistosoma infection,
which consisted of either stool [45] or urine [46] examin-
ation (see below), depending on whether the area was
endemic for S. mansoni or S. haematobium. Demographic
and anthropometric data were collected through a stan-
dardized history and examination that included height
and weight, measured using standardized techniques
(stadiometers and calibrated scales) [44, 47]. WHO
Anthro software (version 3.2.2) was used to calculate age
specific Z scores for height and weight. Significant wasting
was defined as a body mass index (BMI)-for-age Z-score
of < −2, and growth stunting was defined as a height-for-
age Z-score of < −2. Symptom burden and well-being
were assessed using PedsQL, a validated instrument with
multiple domains for measuring health-related quality of
life (HRQoL) in children [27, 48].
Kenya and Tanzania used two different versions of the
PedsQL survey. Kenya used a longer 23-question version
than did Tanzania, which used the 16-question version
with 15 of them adopted but the last question left out
due to irrelevance [24]. To check the validity of combin-
ing the PedsQL scores from the two S. mansoni coun-
tries, we abstracted a subset of Kenya questions that
were the same as Tanzania’s and performed a sensitivity
comparison. The Cronbach’s alpha between the long ver-
sion and short version of Kenya PedsQL scores was 0.93,
reflecting an excellent level of internal consistency. Both
Niger and Mozambique used the long version of PedsQL
having 23 items.
To assess aerobic fitness, all children performed a 20-
m shuttle run per standard protocol [23, 25]. The shuttle
run data were then converted to an estimated maximal
oxygen consumption (VO2 max) [23], a measure of the
maximum volume of oxygen that a subject can utilize
during exertion. The typical normal range of VO2 max
for healthy 8 year old schoolchildren is 43–60 mL/kg/
min [26]. Hemoglobin was measured using capillary
blood; anemia was defined as hemoglobin <11.5 g/dl for
children residing below 1000 m altitude (Niger and
Mozambique, and <11.7 for children residing at the
~1200 m altitude near Lake Victoria (Kenya and
Tanzania) [49]. Abdominal and urographic ultrasounds
were performed on cohort children according to WHO
Niamey protocols [29]. In S. mansoni-endemic commu-
nities, liver texture patterns were graded from A-F, and
those graded C–F were considered abnormal. Portal vein
dilation was scored based on subject height-specific
standards found in the protocol [29]. Normal main por-
tal vein width values are <7 mm for a 90 cm tall child,
and <12 mm for a 170 cm child. Because the baseline
ultrasound data collected in Mozambique were lost, the
results of urogenital ultrasounds are not reported in our
combined analysis.
Laboratory methods
Stool and urine specimens were collected from children
and evaluated for presence of Schistosoma eggs. At S.
mansoni study sites, stool samples were collected on
three consecutive days from each child; two slides con-
taining standardized smears prepared from each stool
were examined by an experienced technician using the
Kato-Katz method [45] and the eggs enumerated. For S.
haematobium, two 10 ml aliquots from a single mid-day
urine specimen were filtered [46] and the eggs counted
by two independent, experienced technicians. A subject
was deemed positive for S. mansoni infection if eggs
were detected in at least one of the six Kato-Katz slides,
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and a subject was deemed positive for S. haematobium
infection if at least one urine aliquot tested positive for
eggs by filtration.
Intensity of infection was measured by counting num-
bers of eggs observed in each of six Kato-Katz samples
for S. mansoni and in each of the two 10 mL filtered
urine samples for S. haematobium. For S. mansoni, the
actual egg counts were converted to eggs per gram (epg)
by simple multiplication times 24 [45]. Egg counts for S.
haematobium are given as eggs per 10 mL of urine
(ep10mL). Based on the WHO guidelines [9], intensities
of infections were categorized as light (1–99 epg), mod-
erate (100–399 epg), or heavy (≥400 epg) for S. mansoni
infections, and as light (1–49 ep10mL) and heavy (≥ 50
ep10mL) for S. haematobium infections.
Statistical methods
For purposes of presentation of baseline cohort charac-
teristics in this paper, children from the two S. mansoni
sites (Tanzania and Kenya) were combined into one co-
hort dataset, and children from the two S. haematobium
sites (Mozambique and Niger) were combined into a
second cohort dataset. As planned in the cohort study
design, all main analyses were performed separately on
S. mansoni and S. haematobium datasets due to the
significant biological differences between S. mansoni and
S. haematobium infection-related pathologies.
Simple univariate and bivariate analyses were used to
describe study participants’ demographics. Chi-square tests
and t-tests were performed to compare results from
children who were egg-positive with those who were not.
Linear or generalized linear mixed models that adjusted for
over-dispersion and clustering effect at the village level
were used to describe patterns of morbidity markers as a
function of predictors of interest. Predictors used in our
multivariable models were chosen mainly based on expert
opinion and adjusted for common factors such as age and
gender. Models for VO2 max were only adjusted for sex,
but not age, because age is used to calculate VO2 max from
the 20-m shuttle run results. To evaluate for the potential
effects of missing outcomes data, multiple imputation for
missing values was implemented as a sensitivity analysis
[50, 51]. All analyses initially conducted for available cases
were later repeated on datasets with missing data being
imputed multiple times, from which new statistical infer-
ence results were made, and these were compared with
those generated from the original dataset. Data analyses
were performed using SAS version 9.4 (SAS Institute Inc.,
Cary, NC). An α = 0.05 level was used for significance of all
statistical tests and for the confidence interval calculations.
The morbidity markers in the cohort study were
considered secondary outcomes of the cross-sectional
studies, which were powered to detect the impact of
alternative approaches to MDA treatment on measures
of infection. Because the expected treatment impact on
infection status per intervention arm was unknown,
power analysis for the cohort studies’ morbidity markers
was not done. However, to maximize chances of estab-
lishing specific intervention-related effects, we enrolled
the largest sample possible given the available resources.
Ethics statement: human subjects participation
Human subjects participated under protocols reviewed and
supervised by institutional review panels in each African
country and by their academic partners. The University of
Georgia (UGA) Institutional Review Board conducted an
administrative review of each cohort study to ensure that
all individual panel reviews met UGA human subjects
protection requirements. Written informed consent was
obtained from parents of children in the study, and assent
was obtained from participating children.
Results
The SCORE morbidity combined cohorts had the follow-
ing baseline characteristics: 2443 children from 36 villages
in 4 countries were enrolled in the cohort at baseline –
1373 in the combined S. mansoni group and 1070 in the
combined S. haematobium group. The four countries:
Kenya, Tanzania, Niger, and Mozambique, enrolled 801,
572, 799, and 271 subjects, respectively. Baseline sample
characteristics for each individual country are listed in
Additional file 1: Tables S1-S4. Enrollment targets for
participation were reached in Kenya and Niger, but not in
Tanzania, while in Mozambique, inadvertent enrollment
of children whose ages were not in cohort range resulted
in the subsequent exclusion of 361 participants.
Cohort baseline characteristics
Combined S. mansoni cohorts
Children in the combined S. mansoni cohort (Tanzania and
Kenya) had an average age at enrollment of 7.5 years, and
53% were female (Table 2). Sixty-two percent of the
children were overtly infected with S. mansoni (egg posi-
tive), with 33%, 20%, and 10% of the total S. mansoni cohort
populations having light, moderate, or heavy infection
intensities, respectively.
Prevalence of stunting and wasting were 7% and 20%,
respectively, among children in the S. mansoni cohort,
and, overall, 36% of the S. mansoni group children were
anemic. All but 5% of children completed liver ultrasound
examinations. Of those with ultrasound data, 86% had
liver pattern A, 13% had liver pattern B, and <1% had liver
pattern C or higher. Among all the enrolled subjects, mea-
sured mean portal vein diameter was 7.2 mm and mean
VO2 max was 49.0 ml/kg/min. Mean total score on the
PedsQL HRQoL assessment was 85 out of 100, with the
means of its four subdomains (physical, emotional, social,
and school) being 89, 75, 92, and 81, respectively.
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Combined S. haematobium cohorts
For the combined data from the S. haematobium country
cohorts (Mozambique and Niger), mean age at enrollment
was 7.5 years, and 49% of the subjects were female (Table 2).
Prevalence of egg-positive S. haematobium infection across
these two cohorts was 27%, with 22% and 5% of the total
population having light and heavy infection intensities,
respectively. Overall prevalence of stunting was 22%, and
12% were wasted. Fifty percent of the S. haematobium
group children (egg-positive and egg-negative) were anemic.
Among all the enrolled subjects, mean VO2 max was
50.2 ml/kg/min. The mean total PedsQL score was 87, with
the means of subdomains (physical, emotional, social, and
school) at 87, 93, 84, and 85, respectively.
Univariate associations with infection
There were no significant differences between egg-negative
and egg-positive children in anthropometric measures or
shuttle run performance among children enrolled in either
the S. mansoni or S. haematobium combined cohorts.
There were no significant differences in liver ultrasound
scores in the combined S. mansoni cohort. Among children
in the S. mansoni combined cohort, only the emotional
subdomain of PedsQL score and hemoglobin were found
to be significantly different between egg-positive and egg-
negative groups, with S. mansoni egg-positive children hav-
ing a lower mean PedsQL emotional sub-score (73.7 vs.
76.0, P = 0.01) and lower hemoglobin levels (11.8 g/dL vs.
12.1 g/dL, P = 0.01) (Table 3).
In the combined S. haematobium cohort, egg-positive
children had mean age that was similar to that of egg-
negative children. Egg-positive children had a higher
prevalence of anemia (64% vs. 44%, P < 0.01) and lower
hemoglobin levels (11.0 g/dL vs. 11.5 g/dL, P < 0.01) than
egg-negative children. In addition, all PedsQL scores
(Total score and physical, emotional, social, and school
subscales) were significantly lower among S. haematobium
egg-positive vs. egg-negative participants (Table 3).
Multiply-adjusted models
In multivariable-adjusted models for the combined S.
mansoni cohort, heavy intensity of S. mansoni infection
was positively associated with anemia (Table 4). However,
having moderate and heavy intensity of infection had
apparent protective effects against wasting (Table 5).
Models considering VO2 max, stunting, liver pattern, and
total and all subdomain PedsQL scores did not indicate
statistically significant associations between those out-
comes and infection intensity. Summary results for all
adjusted models performed for the combined S. mansoni
cohorts can be found in Additional file 1: Table S5.
In the combined S. haematobium cohort, light inten-
sity of S. haematobium infection was positively associ-
ated with anemia. The adjusted odds ratio for those with
heavy intensity infection was similar in magnitude, but it
did not achieve statistical significance (Table 6). Models
considering VO2 max, stunting, wasting, and total and
physical, emotional, and school subdomain PedsQL
scores did not yield statistically significant associations
with infection intensity. Summary results for all adjusted
models performed for the combined S. haematobium
cohorts are presented in Additional file 1: Table S6.
Sensitivity analysis for effects of missing data using
multiple imputation
All of the analyses above were based on inclusion of only
those cases having complete data. As a sensitivity check,
the potential impact of missing data was investigated
through multiple imputation using the fully conditional
specification (FCS) approach [52, 53], after which we re-
peated our analyses on the imputed datasets. The results
from the imputed datasets did not differ significantly,
and the changes in estimated effect sizes were negligible.
Table 2 Participant characteristics for the combined cohorts
Characteristics S. mansoni S. haematobium
N = 1373 N = 1070
n % n %
Schistosome egg-positive children 843 62%† 281 27%
Female 721 53% 524 49%
Infection intensity of egg-positive children
Light (1–99 epg; 1–49 eggs/10 mL) 439 33% 231 22%
Moderatea (100–399 epg) 264 20% NAa NAa
Heavy (≥ 400 epg; ≥50 eggs/ 10 mL) 140 10% 50 5%
Stunting 88 7% 232 22%
Wasting 262 20% 123 12%
Anemia 549 42% 513 50%
Liver Pattern
A 1120 86% –
B 174 13% –
C and above 7 <1% –
mean SD mean SD
Age (years) 7.5 0.5 7.5 0.5
VO2 (mL/kg/min) 49.0 3.2 50.2 3.4
Portal vein diameter (mm) 7.2 1.1 –
PedsQL Total 84.6 12.7 86.6 19.9
Physical 89.1 16.8 87.4 24.1
Emotional 74.5 15.7 92.9 14.5
Social 91.6 16.5 84.0 27.2
School 80.5 17.5 85.0 15.9
†Not equal to the sum of light, moderate, and heavy infection prevalence due
to rounding
aS. haematobium intensity is classified as light or heavy; there is no
intermediate intensity
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Discussion
This paper describes the process we used for developing
the cohort studies nested in the SCORE multi-country
parallel randomized trials of drug-based control of schis-
tosomiasis in sub-Saharan Africa, and provides the base-
line data. These cohort studies serve as pragmatic
comparative effectiveness trials, in that they take advan-
tage of a unique opportunity to explore effects of two
very different approaches to multi-year MDA on mor-
bidity associated with either S. mansoni or S. haemato-
bium infection among children. The present study asks
the question: does annual community-wide treatment
with praziquantel result in incremental health benefits in
terms of physical growth and development, exercise tol-
erance, hemoglobin levels and anemia, liver ultrasound
findings, and health-related quality-of-life, in comparison
to every-other-year treatment administered through a
school-based program?
The cohort design development targeted children aged 7
to 8 years old to maximize potential follow up participation
throughout the five-year period of the project. Mozambique
enrolled Standard 1 (First grade) students; however, because
of students’ irregular school attendance, a significant pro-
portion of these had ages outside the targeted 7–8 year old
age range. As a consequence, the participation of children
meeting protocol inclusion criteria in S. haematobium
countries was lower than that in the S. mansoni cohort.
Prevalence of Schistosoma infection was lowest in
Niger. The villages assigned to Arm A (4 years of CWT)
had the lowest mean prevalence of all study arms in
Niger [12]. Given that the purpose of the cohort study is
to assess differences in morbidity markers between
balanced study arms, the baseline Niger data are given
in this paper, but because of potential trial outcomes
bias caused by this imbalance, the Niger cohort was
terminated after the baseline data collection.
Table 3 Univariable relationships with egg-positive infectiona
S. mansoni countries S. haematobium countries
S. mansoni egg-positive S. mansoni egg-negative S. haematobium egg-positive S. haematobium egg-negative
N = 843 N = 507 N = 281 N = 771
n % n % P value n % n % P value
Female 436 52% 275 54% 0.37 138 49% 377 49% 0.95
Stunting 56 7% 32 7% 0.90 67 21% 163 25% 0.22
Wasting 164 20% 95 20% 0.88 26 10% 96 13% 0.21
Anemia 366 44% 182 38% 0.02 172 64% 331 44% < 0.01
mean SD mean SD P value mean SD mean SD P value
Age 7.5 0.5 7.5 0.5 0.20 7.5 0.5 7.5 0.5 0.25
VO2 49 3.2 49 3.1 0.62 50.1 3.7 50.2 3.3 0.81
Hemoglobin 11.8 2.3 12.1 2.1 0.01 11.0 1.6 11.5 1.6 < 0.01
PedsQL
Total 84.3 12.9 85 12.5 0.33 80.7 21.9 89.3 18.0 < 0.01
Physical 89 16.1 89.1 18 0.99 81.8 27.4 90.1 21.8 < 0.01
Emotional 73.7 15.9 76 15.5 0.01 89.4 17.4 94.4 13.0 < 0.01
Social 91.9 16.4 91.3 16.8 0.54 75.6 32.0 87.8 23.6 < 0.01
School 79.8 17 81.7 18.3 0.08 78.2 15.1 87.4 15.4 < 0.01
aNumbers in each category may be less than the total number of children in each cohort because of missing data. Bold font indicates statistically significant
differences at the P < 0.05 level
Table 4 Multivariable models for anemia in S. mansoni cohortsa
Predictors Adjusted OR 95% CI Unadjusted OR 95% CI
S. mansoni Egg-negative Reference Reference Reference Reference
Light intensity 1.05 (0.79, 1.40) 1.05 (0.79, 1.40)
Moderate intensity 1.38 (0.98, 1.93) 1.37 (0.98, 1.93)
Heavy intensity 1.78 (1.16, 2.72) 1.78 (1.16, 2.72)
Age in years 0.90 (0.71, 1.14) – –
Female 0.95 (0.76, 1.20) – –
aBold font indicates statistically significant differences at the P < 0.05 level
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Despite higher infection prevalence, the combined S.
mansoni cohort had lower anemia prevalence than the
combined S. haematobium cohort. The S. mansoni and
S. haematobium cohorts also showed differences in the
proportion of children who had growth stunting and
wasting. The S. mansoni cohorts (Kenya and Tanzania)
had a relatively low combined stunting rate and a mod-
erate wasting rate, whereas in the S. haematobium
cohort (Mozambique and Niger), the situation was
reversed: stunting was more prevalent and wasting less
prevalent in these locations affected by urogenital schis-
tosomiasis. Growth stunting reflects long term undernu-
trition or chronic disease, while wasting implies
somewhat normal linear growth followed by a more
acute period of undernutrition that reduces the velocity
of weight gain, or worse, causes weight loss, which
affects the age-adjusted BMI Z-score [54].
In agreement with other studies, our baseline cohort
data indicated significant associations between active (egg-
positive) Schistosoma infection and hemoglobin/anemia in
most of the univariate and all of the multivariate models.
In contrast, our results suggesting that moderate and
heavy intensity of S. mansoni infection had protective
effects on wasting (Table 5) were unexpected. Additional
explorations revealed that average weights were similar in
subjects with different intensity level of S. mansoni infec-
tion, but cohort children who were moderately and heavily
infected tended to be shorter. This could have led to a
relative increase in the calculated BMIs in those partici-
pants (Additional file 1: Table S7).
In terms of study limitations, these cohort studies had
relatively low sample size of children experiencing mor-
bidity, and so they may not have the power to detect
statistically significant differences between infected and
egg-negative children at baseline. The numbers of vil-
lages enrolled for the cohort studies from each country
varied from 7 to 12. Because village clustering effects
were adjusted for in multivariate models, our power to
detect statistically significant differences in those models
was more limited [55, 56]. It is possible that there were
unmeasured confounders that could have affected mor-
bidity markers, e.g., the impact of concurrent malaria on
anemia [56]. Some additional factors were measured in
individual country cohorts, e.g., malaria was measured in
Kenya and Niger [56], but it was not possible to include
these factors across the combined-cohort analysis
presented here.
A relative strength of these cohort studies is their abil-
ity to measure and monitor morbidity markers in a lon-
gitudinal fashion. Even if final prevalence and intensity
differences between the comparison groups are smaller
than anticipated, children in Arm A will be treated
annually in contrast to treatment every other year in
Arm B, and, therefore, Arm A children will potentially
spend more time in an uninfected state, which should,
in theory, reduce development of Schistosoma-associated
morbidity.
In initiating these cohort studies, we have demon-
strated the practicality and challenges of enrolling large
numbers of children into longitudinal cohorts, and of
monitoring multiple morbidity markers among children
in field studies. Some of our sites, such as Mozambique,
had relatively little parasite control infrastructure prior
to the initiation of the SCORE studies. Nevertheless,
they were able to complete these baseline studies. The
loss of the baseline ultrasound data in Mozambique was
Table 5 Multivariable models for wasting in S. mansoni cohortsa
Predictors Adjusted OR 95% CI Unadjusted OR 95% CI
S. mansoni Egg-negative Reference Reference Reference Reference
Light intensity 0.87 (0.60, 1.27) 0.88 (0.61, 1.28)
Moderate intensity 0.45 (0.28, 0.73) 0.45 (0.28, 0.72)
Heavy intensity 0.38 (0.21, 0.71) 0.37 (0.20, 0.69)
Age in years 0.89 (0.65, 1.20) – –
Female 0.82 (0.61, 1.11) – –
aBold font indicates statistically significant differences at the P < 0.05 level
Table 6 Multivariable models for anemia in S. haematobium cohortsa
Predictors Adjusted OR 95% CI Unadjusted OR 95% CI
S. haematobium Egg-negative Reference Reference Reference Reference
Light intensity 1.70 (1.18, 2.45) 1.74 (1.21, 2.51)
Heavy intensity 1.64 (0.86, 3.16) 1.68 (0.87, 3.22)
Age in years 0.73 (0.56, 0.96) – –
Female 0.88 (0.68, 1.14) – –
aBold font indicates statistically significant differences at the P < 0.05 level
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unfortunate, but the examinations themselves were con-
ducted without a problem. We look forward to the final
outcomes of the cohort study and to further assessment
of the utility of our morbidity markers in measuring the
impact of different strategies used to deliver anti-
schistosomal MDA. Continued follow up of the enrolled
cohorts will allow better estimates of the interim (Year
3) and longer-term (Year 5) benefits of participation in
more- or less-intensive standardized MDA programs
(Arm A vs. Arm B). Analyses should be able to quantify
the magnitude of MDA effects on infection intensity, as
well as on infection-related organ damage, anemia,
growth, fitness, and health-related quality-of-life. It is ex-
pected that this empiric evidence can help to guide
future ‘preventive chemotherapy’ approaches [10] to
schistosomiasis morbidity control.
Conclusions
Our consensus on practical markers of Schistosoma-associ-
ated morbidity indicated that height, weight, hemoglobin,
exercise tolerance, HRQoL, and ultrasound abnormalities
could be used as reference points for gauging treatment
impact. Data collected over five years of program imple-
mentation will provide guidance for future evaluation of
morbidity control in areas endemic for schistosomiasis.
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Abbreviations
BMI: Body mass index; CWT: Community-wide treatment; ECP: Eosinophil
cationic protein; EP10ML: Schistosoma haematobium eggs per 10 mL urine;
EPG: Schistosoma mansoni eggs per gram feces; HRQoL: Health-related
quality of life; ISRCT: International Standard Randomised Controlled Trial
Registry; MDA: Mass drug administration; MUAC: Mid-upper arm
circumference; PEDSQL: Pediatric quality of life inventory questionnaire and
scale; SBT: School-based treatment; SCORE: Schistosomiasis Consortium for
Operational Research and Evaluation; UGA: University of Georgia; VO2
max: Maximum volume of oxygen uptake during exercise in mL per
kilogram body weight per minute; WHO: World Health Organization
Acknowledgements
The authors wish to thank Nupur Kittur and Jennifer D. Castleman for
invaluable assistance with data management, and Steve Rathbun for
participation in the early development of this project.
Funding
These studies received financial support from University of Georgia Research
Foundation, Inc., which was funded by the Bill & Melinda Gates Foundation
for the SCORE project. The funders had no role in the study design, data
collection and analysis, decision to publish, or preparation of the manuscript.
Availability of data and materials
All data supporting our findings are already contained within this
manuscript.
Data analysis
YS implemented data analysis, in collaboration with FZ and CCW.
Disclaimers
The findings and conclusions in this report are those of the authors and do
not necessarily represent the views of the CDC.
Study design/conceptualization
This SCORE project was designed and conceptualized by a team of United
States and international collaborators: DGC, CHK, SB, CHC, WES, SPM, PNMM,
AO, PM, SK, AF, AEP, RN, JF, AH, and AG.
Authors’ contributions
Each author contributed to data interpretation and manuscript development,
critique and revision for important intellectual content by providing
comment, reading, editing and approving the final version of the
manuscript. YS, CHK, SB, FZ, CCW, WES, SPM, PNMM, AO, PM, SK, AEP, JF,
HOA, FF, AG, AH, AF, CHC, and DGC.
Authors’ information
The Schistosomiasis Consortium for Operational Research and Evaluation
(SCORE) was established in December 2008 to answer strategic questions
about schistosomiasis control and elimination. SCORE is funded by the Bill &
Melinda Gates Foundation through a ten-year grant to the University of
Georgia Research Foundation (UGARF).
SCORE’s goal is to find answers that will help current and future
schistosomiasis control program managers to do their job better. This
includes learning what approaches to controlling and eliminating
schistosomiasis work best and developing and evaluating new tools for
program managers to use. Our vision is that our work will inform efforts to
gain control of schistosomiasis in high-prevalence areas, sustain control and
move towards elimination in areas of moderate prevalence, and ultimately
eliminate schistosomiasis. SCORE does this by funding investigators from
around the world to conduct the needed research and evaluation activities.
The SCORE Secretariat is located on the campus of the University of Georgia
in Athens, Georgia, USA, within the Center for Tropical and Emerging Global
Diseases (CTEGD), but the program involves many investigators from around
the globe.
Ethics approval and consent to participate
Written informed consent was obtained from parents/legal guardians of
children in the study and assent was obtained from participating children,
who were 7–8 years old. Ethical review of the research protocols was
implemented by human subjects committee in each African country and by
the institutional review board (IRB) of their respective northern partners.
Studies in Kenya were reviewed and approved by the National Ethics Review
Committee of the Kenyan Medical Research Institute.
(KEMRI; approval number SCC 1820) and by the IRB of the Centers for
Disease Control and Prevention (CDC; approval #: 1661). In Niger, ethical
approval was obtained from the Niger Republic National Consulate for
ethical review (reference no.012/2010/CCNE) and from the Imperial College
Research Ethic Committee (ICREC_8_2_2). In Mozambique, ethical approval
was received from the Ministry of Health (reference no. 235/CNBS/10) and
the Imperial College Research Ethic Committee (ICREC_10_8_2). In Tanzania,
ethical approval was obtained from the National Institute for Medical
Research (NIMR; reference no. NIMR/HQ/R.8a/Vol. IX/1022). In addition to
these, the UGA IRB implemented an administrative human subjects review
and issued additional approval per country’s protocol as follows: 10,267–0,
10,353–0, 10,431–0, and 10,533–0; for Kenya, Tanzania, Niger, and
Mozambique, respectively. The parent trials have been registered with the
International Standard Randomised Controlled Trial registry under ISRCT
numbers 16,755,535 (Kenya), 95,819,193 (Tanzania), 32,045,736 (Niger), and
14,117,624 (Mozambique). Following enrollment and initial morbidity testing,
all participating egg-positive and egg-negative subjects received treatment
with 40 mg/kg praziquantel according to the approved SCORE Project MDA
protocols.
Consent for publication
This paper is published with permission of the Director, KEMRI.
Competing interests
The authors declare that they have no competing interests.
Shen et al. BMC Infectious Diseases  (2017) 17:652 Page 9 of 11
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Department of Epidemiology and Biostatistics, University of Georgia, Athens,
GA, USA. 2Center for Global Health and Diseases, Case Western Reserve
University, Cleveland, OH, USA. 3Schistosomiasis Consortium for Operational
Research and Evaluation, Center for Tropical and Emerging Global Diseases
and Department of Microbiology, University of Georgia, Athens, GA, USA.
4Parasitic Diseases Branch, Division of Parasitic Diseases and Malaria, Centers
for Disease Control and Prevention, Atlanta, GA, USA. 5Centre for Global
Health Research, Kenya Medical Research Institute, Kisumu, Kenya.
6Parasitology and Aquatic Diseases, Faculty of Health and Medical Sciences,
University of Copenhagen, Copenhagen, Denmark. 7National Institute for
Medical Research, Mwanza Research Centre, Mwanza, Tanzania.
8Schistosomiasis Control Initiative, Department of Infectious Disease
Epidemiology, Imperial College, London, UK. 9Instituto Nacional de Saúde,
Maputo, Mozambique. 10Universidade Católica de Moçambique, Beira,
Mozambique. 11Réseau International Schistosomoses, Environnement,
Aménagement et Lutte (RISEAL-Niger), Niamey, Niger.
Received: 20 July 2017 Accepted: 14 September 2017
References
1. Colley DG, Bustinduy AL, Secor WE, King CH. Human schistosomiasis. Lancet.
2014;383(9936):2253–64.
2. Steinmann P, Keiser J, Bos R, Tanner M, Utzinger J. Schistosomiasis and
water resources development: systematic review, meta-analysis, and
estimates of people at risk. Lancet Infect Dis. 2006;6(7):411–25.
3. King CH, Dickman K, Tisch DJ. Reassessment of the cost of chronic
helmintic infection: a meta-analysis of disability-related outcomes in
endemic schistosomiasis. Lancet. 2005;365(9470):1561–9.
4. Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al.
Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21
regions, 1990–2010: a systematic analysis for the global burden of disease
study 2010. Lancet. 2013;380(9859):2197–223.
5. Kabatereine N, Kemijumbi J, Ouma J, Kariuki H, Richter J, Kadzo H, et al.
Epidemiology and morbidity of Schistosoma mansoni infection in a fishing
community along Lake Albert in Uganda. Trans R Soc Trop Med Hyg. 2004;
98(12):711–8.
6. Salam RA, Maredia H, Das JK, Lassi ZS, Bhutta ZA. Community-based
interventions for the prevention and control of helmintic neglected tropical
diseases. Infect Dis Poverty. 2014;3(1):1.
7. Vennervald B, Ouma J, Butterworth A. Morbidity in schistosomiasis:
assessment, mechanisms and control. Parasitol Today. 1998;14(10):385–90.
8. Woolhouse M, Mutapi F, Ndhlovu P, Chandiwana S, Hagan P. Exposure,
infection and immune responses to Schistosoma haematobium in young
children. Parasitology. 2000;120(01):37–44.
9. WHO. Prevention and control of schistosomiasis and soil-transmitted
helminthiasis: report of a WHO expert committee. Technical Report Series.
Geneva: World Health Organization; 2002. Report No.: 912
10. WHO. Preventive chemotherapy in human helminthiasis: coordinated use of
anthelminthic drugs in control interventions: a manual for health
professionals and programme managers. Geneva: World Health
Organization; 2006.
11. Colley DG. Morbidity control of schistosomiasis by mass drug
administration: how can we do it best and what will it take to move on to
elimination? Trop Med Health. 2014;42(2SUPPLEMENT):S25–32.
12. Ezeamama AE, He C-L, Shen Y, Yin X-P, Binder SC, Campbell CH, et al.
Gaining and sustaining schistosomiasis control: study protocol and baseline
data prior to different treatment strategies in five African countries. BMC
Infect Dis. 2016;16(1):1.
13. Ezeamama AE, McGarvey ST, Acosta LP, Zierler S, Manalo DL, Wu HW, et al.
The synergistic effect of concomitant schistosomiasis, hookworm, and
Trichuris infections on children's anemia burden. PLoS Negl Trop Dis. 2008;
2(6):e245. doi:10.1371/journal.pntd.0000245.
14. Leenstra T, Coutinho HM, Acosta LP, Langdon GC, Su L, Olveda RM, et al.
Schistosoma japonicum reinfection after praziquantel treatment causes
anemia associated with inflammation. Infect Immun. 2006;74(11):6398–407.
15. Righetti AA, Adiossan LG, Ouattara M, Glinz D, Hurrell RF, N'Goran EK, et al.
Dynamics of anemia in relation to parasitic infections, micronutrient status,
and increasing age in south-central Cote d'Ivoire. J Infect Dis. 2013;207(10):
1604–15. doi:10.1093/infdis/jit066.
16. Bustinduy AL, Parraga IM, Thomas CL, Mungai PL, Mutuku F, Muchiri EM, et
al. Impact of polyparasitic infections on anemia and undernutrition among
Kenyan children living in a Schistosoma haematobium-endemic area. Am J
Trop Med Hyg. 2013;88:433–40. doi:10.4269/ajtmh.12-0552.
17. Parraga IM, Assis AM, Prado MS, Barreto ML, Reis MG, King CH, et al. Gender
differences in growth of school-aged children with schistosomiasis and
geohelminth infection. Am J Trop Med Hyg. 1996;55(2):150–6.
18. Stephenson LS, Latham MC, Kurz KM, Kinoti SN. Single dose metrifonate or
praziquantel treatment in Kenyan children. II. Effects on growth in relation
to Schistosoma haematobium and hookworm egg counts. Am J Trop Med
Hyg. 1989;41(4):445–53.
19. Ezeamama AE, Bustinduy AL, Nkwata AK, Martinez L, Pabalan N, King CH.
Cognitive deficits and loss of education with human Schistosoma species
infection – a systematic review and meta-analysis. PLoS Negl Trop Dis. 2017;
(in press)
20. Fenwick A, Webster JP, Bosque-Oliva E, Blair L, Fleming FM, Zhang Y, et al.
The Schistosomiasis Control Initiative (SCI): rationale, development and
implementation from 2002-2008. Parasitology. 2009;136(13):1719–30.
doi:10.1017/S0031182009990400.
21. Woodhall DM, Wiegand RE, Wellman M, Matey E, Abudho B, Karanja DM,
et al. Use of geospatial modeling to predict Schistosoma mansoni
prevalence in Nyanza Province, Kenya. PLoS One. 2013;8(8):e71635.
doi:10.1371/journal.pone.0071635.
22. Baird S, Hicks JH, Kremer M, Miguel E. Worms at work: long-run impacts of a
child health investment. Q J Econ. 2016;131(4):1637–80. doi:10.1093/qje/
qjw022.
23. Leger LA, Lambert J. A maximal multistage 20-m shuttle run test to predict
VO2 max. Eur J Appl Physiol Occup Physiol. 1982;49(1):1–12.
24. Kinung’hi S, Magnussen P, Kaatano G, Olsen A. Infection with Schistosoma
mansoni has an effect on quality of life, but not on physical fitness in
schoolchildren in Mwanza region, north-western Tanzania: a cross-sectional
study. PLoS Negl Trop Dis. 2016;10(12):e0005257.
25. Leger L, Lambert J, Goulet A, Rowan C, Dinelle Y. Capacité aérobie des
Québécois de 6 à 17 ans - Test navette de 20 mètres avec paliers de 1
minute. Can J Appl Spt Sci. 1984;9:64–9.
26. Leger LA, Mercier D, Gadoury C, Lambert J. The multistage 20 metre shuttle
run test for aerobic fitness. J Sports Sci. 1988;6(2):93–101.
27. Terer CC, Bustinduy AL, Magtanong RV, Muhoho N, Mungai PL, Muchiri EM,
et al. Evaluation of the health-related quality of life of children in
Schistosoma haematobium-endemic communities in Kenya: a cross-sectional
study. PLoS Negl Trop Dis. 2013;7(3):e2106. doi:10.1371/journal.pntd.
0002106.
28. Furst T, Silue KD, Ouattara M, N'Goran DN, Adiossan LG, N'Guessan Y, et al.
Schistosomiasis, soil-transmitted helminthiasis, and sociodemographic
factors influence quality of life of adults in Cote d'Ivoire. PLoS Negl Trop Dis.
2012;6(10):e1855. doi:10.1371/journal.pntd.0001855.
29. Richter J, Hatz C, Campagne G, Bergquist NR, Jenkins JM. Ultrasound in
schistosomiasis: a practical guide to the standardized use of
ultrasonography for the assessment of schistosomiasis-related morbidity.
Geneva: World Health Organization; 2000. Report No.: TDR/STR/SCH/00.1
30. Andrade G, Bertsch DJ, Gazzinelli A, King CH. Decline in infection-related
morbidities following drug-mediated reductions in the intensity of
Schistosoma infection: a systematic review and meta-analysis. PLoS Negl
Trop Dis. 2017;11(2):e0005372. doi:10.1371/journal.pntd.0005372.
31. Bustinduy AL, Sutherland LJ, Chang-Cojulun A, Malhotra I, DuVall AS, Fairley
JK, et al. Age-stratified profiles of serum IL-6, IL-10, and TNF-alpha cytokines
among Kenyan children with Schistosoma haematobium, Plasmodium
falciparum, and other chronic parasitic co-infections. Am J Trop Med Hyg.
2015; doi:10.4269/ajtmh.14-0444.
32. Leenstra T, Acosta LP, Langdon GC, Manalo DL, Su L, Olveda RM, et al.
Schistosomiasis japonica, anemia, and iron status in children, adolescents,
and young adults in Leyte, Philippines. Am J Clin Nutr. 2006;83(2):371–9.
33. Kvalsvig JD. The effects of schistosomiasis on spontaneous play activity in
black schoolchildren in the endemic areas. An ethological study. S Afr Med
J. 1981;60(2):61–4.
34. Kvalsvig JD. The effects of schistosomiasis haematobium on the activity of
school children. J Trop Med Hyg. 1986;2:85–90.
Shen et al. BMC Infectious Diseases  (2017) 17:652 Page 10 of 11
35. Musuva R, Shen Y, Wei X, Binder S, Ivy JA, Secor WE, et al. Change in
children's school behavior after mass administration of praziquantel for
Schistosoma mansoni infection in endemic areas of western Kenya: a pilot
study using the behavioral assessment system for children (BASC-2). PLoS
One. 2017;12(7):e0181975. doi:10.1371/journal.pone.0181975.
36. McDonald EA, Cheng L, Jarilla B, Sagliba MJ, Gonzal A, Amoylen AJ, et al.
Maternal infection with Schistosoma japonicum induces a profibrotic response
in neonates. Infect Immun. 2014;82(1):350–5. doi:10.1128/IAI.01060-13.
37. King CH, Bertsch D. Meta-analysis of urine heme dipstick diagnosis of
Schistosomahaematobium infection, including low-prevalence and
previously-treated populations. PLoS Negl Trop Dis. 2013;7(9):e2431.
doi:10.1371/journal.pntd.0002431.
38. Leutscher PD, Reimert CM, Vennervald BJ, Ravaoalimalala VE, Ramarokoto
CE, Serieye J, et al. Morbidity assessment in urinary schistosomiasis infection
through ultrasonography and measurement of eosinophil cationic protein
(ECP) in urine. Tropical Med Int Health. 2000;5(2):88–93.
39. Parker M. Re-assessing disability: the impact of schistosomal infection on
daily activities among women in Gezira Province. Sudan Soc Sci Med.
1992;35(7):877–90.
40. Kloos H, Ouma J, Kariuki HC, Butterworth AE. Knowledge, perceptions and
health behavior pertaining to Schistosoma mansoni related illness in
Machakos district. Kenya Trop Med Parasitol. 1986;37(2):171–5.
41. Kjetland EF, Kurewa EN, Mduluza T, Midzi N, Gomo E, Friis H, et al. The first
community-based report on the effect of genital Schistosoma haematobium
infection on female fertility. Fertil Steril. 2010;94(4):1551–3. doi:10.1016/j.
fertnstert.2009.12.050.
42. Friedman JF, Mital P, Kanzaria HK, Olds GR, Kurtis JD. Schistosomiasis and
pregnancy. Trends Parasitol. 2007;23(4):159–64.
43. Malhotra I, McKibben M, Mungai P, McKibben E, Wang X, Sutherland LJ,
et al. Effect of antenatal parasitic infections on anti-vaccine IgG levels in
children: a prospective birth cohort study in Kenya. PLoS Negl Trop Dis.
2015;9(1):e0003466. doi:10.1371/journal.pntd.0003466.
44. Bustinduy AL, Thomas CL, Fiutem JJ, Parraga IM, Mungai PL, Muchiri EM,
et al. Measuring fitness of Kenyan children with polyparasitic infections
using the 20-meter shuttle run test as a morbidity metric. PLoS Negl Trop
Dis. 2011;5(7):e1213. doi:10.1371/journal.pntd.0001213.
45. Katz N, Chaves A, Pellegrino J. A simple device for quantitative stool thick-
smear technique in schistosomiasis mansoni. Rev Inst Med Trop Sao Paulo.
1972;14:397–400.
46. Peters PAS, Mahmoud AAF, Warren KS, Ouma JH, Siongok TKA. Field studies
of a rapid, accurate means of quantifying Schistosoma haematobium eggs
in urine samples. Bull World Health Organ. 1976;54:159–62.
47. Jelliffe DB. The assessment of the nutritional status of the community (with
special reference to field surveys in developing regions of the world).
Monogr Ser World Health Organ. 1966;53:3–271.
48. Varni JW, Limbers CA, Burwinkle TM. How young can children reliably and
validly self-report their health-related quality of life?: an analysis of 8,591
children across age subgroups with the PedsQL™ 4.0 generic Core scales.
Health Qual Life Outcomes. 2007;5(1):1.
49. WHO. Haemoglobin concentrations for the diagnosis of anaemia and
assessment of severity (WHO/NMH/NHD/MNM/11.1). Vitamin and Mineral
Nutrition Information System. Geneva: World Health Organization; 2011.
50. Sterne JA, White IR, Carlin JB, Spratt M, Royston P, Kenward MG, et al.
Multiple imputation for missing data in epidemiological and clinical
research: potential and pitfalls. BMJ. 2009;338:b2393.
51. Yuan YC. Multiple imputation for missing data: concepts and new
development (version 9.0). SAS Institute Inc, Rockville, MD. 2010; 49.
52. Little RJ. Pattern-mixture models for multivariate incomplete data. J Am Stat
Assoc. 1993;88(421):125–34.
53. Liu Y, De A. Multiple imputation by fully conditional specification for dealing with
missing data in a large epidemiologic study. Int J Stat Med Res. 2015;4(3):287.
54. WHO Multicentre Growth Reference Study Group. WHO child growth
standards: length/height-for-age, weight-for-age, weight-for-length, weight-
for-height and body mass index-for-age: methods and development.
Geneva: World Health Organization. 2006; 312.
55. Cameron AC, Gelbach JB, Miller DL. Bootstrap-based improvements for
inference with clustered errors. Rev Econ Stat. 2008;90(3):414–27.
56. Samuels AM, Matey E, Mwinzi PN, Wiegand RE, Muchiri G, Ireri E, et al.
Schistosoma mansoni morbidity among school-aged children: a SCORE
project in Kenya. Am J Trop Med Hyg. 2012;87(5):874–82.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Shen et al. BMC Infectious Diseases  (2017) 17:652 Page 11 of 11
